Figure 1. The outcomes of high-risk APL patients.
The cumulative incidence rate of hematologic CR and CMR (A), and EFS and OS (B) for high-risk APL patients treated with oral arsenic and ATRA.
The cumulative incidence rate of hematologic CR and CMR (A), and EFS and OS (B) for high-risk APL patients treated with oral arsenic and ATRA.
